Characterizing Rheumatoid Arthritis With 68Ga-FAPI PET/CT

Summary

68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation, such as IgG4-related disease and inflammatory bowel disease. Some researches identified FAP expression in synovial samples taken from both rheumatoid arthritis and osteoarthritis patients.Thus this prospective study is going to investigate whether 68Ga-FAPI PET/CT may be superior for diagnosis, therapy response assessment and follow-up of arthritis than 18F-FDG PET/CT.

Timeline

Start

2020-09-01

Primary completion

2022-01-01

Completion

2022-12-01

Publications

• Yang D, Chen J, He G, Zhou Z, Xu J, Peng Y, Shen X, Jiang X, Pan Q, Zhao L, Fei Y, Luo Y, Yang H. Comparisons of [68 Ga]Ga-FAPI-04 PET/CT with X-ray imaging in the assessment of patients with rheumatoid arthritis. Clin Rheumatol. 2025 Jun;44(6):2191-2199. doi: 10.1007/s10067-025-07414-y. Epub 2025 Apr 28.
• Pan Q, Yang H, Zhou Z, Li M, Jiang X, Li F, Luo Y, Li M. [68 Ga]Ga-FAPI-04 PET/CT may be a predictor for early treatment response in rheumatoid arthritis. EJNMMI Res. 2024 Jan 4;14(1):2. doi: 10.1186/s13550-023-01064-4.

Drugs

Indications